Lauren LeBlanc v. AngioDynamics, Inc., Chad Campbell, Stephanie Pitts, and Chris Davis

CourtDistrict Court, N.D. New York
DecidedJanuary 16, 2026
Docket1:22-cv-00229
StatusUnknown

This text of Lauren LeBlanc v. AngioDynamics, Inc., Chad Campbell, Stephanie Pitts, and Chris Davis (Lauren LeBlanc v. AngioDynamics, Inc., Chad Campbell, Stephanie Pitts, and Chris Davis) is published on Counsel Stack Legal Research, covering District Court, N.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Lauren LeBlanc v. AngioDynamics, Inc., Chad Campbell, Stephanie Pitts, and Chris Davis, (N.D.N.Y. 2026).

Opinion

UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF NEW YORK ________________________________________

LAUREN LEBLANC,

Plaintiff, v. 1:22-cv-229 (ECC/PJE) ANGIODYNAMICS, INC., CHAD CAMPBELL, STEPHANIE PITTS, and CHRIS DAVIS,

Defendants.

________________________________________

APPEARANCES:

Megan Goddard, Esq., for Plaintiff Michael D. Billok, Esq., for Defendants

Elizabeth C. Coombe, United States District Judge:

MEMORANDUM-DECISION & ORDER On January 31, 2022, Plaintiff Lauren LeBlanc filed a complaint in the Supreme Court of the State of New York, County of Albany against Defendants AngioDynamics, Inc., Chad Campbell (Campbell), Stephanie Pitts (Pitts), and Chris Davis (Davis) alleging violations of the New York State Human Rights Law, the Equal Pay Act of 1963 (the federal EPA), and the New York Equal Pay Act (the New York EPA). Dkt. No. 1-1 at 2. Defendants removed the action on March 9, 2022. Dkt. No. 1. Presently before the Court is Defendants’ motion for summary judgment. Dkt. No. 40. The motion is fully briefed. Dkt. Nos. 45, 46. For the following reasons, Defendants’ motion for summary judgment is granted on the federal and New York EPA claims, and the remaining state-law claims are remanded to state court. I. Background1 Defendant AngioDynamics, Inc. (AngioDynamics) provides medical devices to treat “cancer and peripheral vascular diseases.” Def. SUMF ¶ 1. Plaintiff began working for AngioDynamics in March 2013 as an Exhibits and Events Manager, and in December 2014, she

became a Senior Executive Administrative Assistant to the Chief Executive Officer with an annual salary of $85,000. Id. ¶¶ 2, 4, 9. In June 2017, she became an Associate Product Manager (APM) on the Vascular Access Marketing Team (VA Team) with an annual salary of $90,176.84.2 Id. ¶¶ 8-9. During Plaintiff’s employment, she and the other PMs on her team reported to managers at levels higher than PM. Def. Resp. ¶ 1. According to Plaintiff, APMs “typically report[ed] to and support[ed] a [PM], who manage[d] product lines or launches” and “assign[ed] work supporting their products and their market strategy to the APM.” Pl. SUMF ¶ 1. Another female APM on Plaintiff’s team was promoted in August of 2018. Dkt. No. 40- 39 ¶ 20. After the other APM’s promotion, Plaintiff’s salary of $95,900 was still higher than that

new PM’s salary of $95,000. Id. ¶¶ 19, 21. While Plaintiff worked as an APM, three other female APMs were on her team at various times. Pl. SUMF ¶¶ 3; Dkt. Nos. 40-39 ¶ 10; 40-44 at 2. Plaintiff initially reported directly to Brad Chartrand, Global Director of Marketing for Vascular Access. Def. SUMF ¶¶ 7, 16. According to Plaintiff, Chartrand told her that she would

1 The facts are drawn from the Defendant’s Statement of Material Facts (Def. SUMF), Dkt. No. 40-51, Plaintiff’s Statement of Additional Material Facts (Pl. SUMF), Dkt. No. 45-2, Plaintiff’s Response to Defendant’s Statement of Material Facts (Pl. Resp. SUMF), Dkt. No. 45-1, and Defendant’s Response to Plaintiff’s Statement of Additional Material Facts (Def. Resp. SUMF), Dt. No. 46-1, and the exhibits that the parties have submitted, to the extent that they are admissible evidence. Disputed facts are noted.

2 At the time, Defendant Campbell was Senior Vice President and General Manager of Vascular Access, and Defendant Pitts was Clinical Marketing Manager for the VA Team. Def. SUMF ¶ 7. likely be promoted to Product Manager in approximately six months because of her previous experience at the company. Id. ¶ 15; Pl. SUMF ¶ 4. Plaintiff was assigned products related to dialysis in the United States, and she managed these products without the management and guidance of a PM. Pl. SUMF ¶ 8. Approximately three months later, Plaintiff began handling

accessories, and she managed that “on her own, without a PM to guide her.” Id. ¶ 9. In September 2017, Plaintiff received the global dialysis market. Id. ¶ 10. In addition, according to Plaintiff, within the first few months in her new role, Chartrand assigned her “PM responsibilities such as managing [her]own product lines” and she “was expected to determine her own marketing strategy.” Id. ¶ 7 (citing Declaration of Lauren LeBlanc (LeBlanc Decl.) ¶ 8, Dkt. No. 45-3). In November 2017, Chartrand left AngioDynamics, and Plaintiff began reporting directly to Defendant Campbell. Def. SUMF ¶¶ 16-17. In November 2017, Plaintiff acquired the ports products on a temporary basis, and she continued to handle those products until she was terminated. Pl. SUMF ¶¶ 10-11. By November 2017, Plaintiff was managing 65 of the 98 products in the VA portfolio, and that was more than either of the other two APMs. Id. ¶ 12. According to

Defendant, Plaintiff’s products generated approximately $40 million in annual global revenue and that was consistent with the other APMs. Def. Resp. SUMF ¶ 12. In May 2018, AngioDynamics hired Defendant Davis to replace Chartrand, and Plaintiff began reporting to him. Def. SUMF ¶ 18. On August 8, 2018, Campbell completed a formal performance evaluation stating that Plaintiff “exceeds expectations” or “meets expectations” in all categories except one, “collaboration,” where the rating was “needs development.” Pl. Resp. SUMF ¶ 21; Dkt. No. 40-19. Plaintiff’s overall score was 3.17, indicating “solid performer.” Id; Dkt. No. 40-17. The parties dispute whether Plaintiff reported that she was experiencing harassment and discrimination from Campbell, Pitts, Davis and others in May and September of 2018. Compare Pl. SUMF ¶¶ 26, 28 with Def. Resp. SUMF ¶¶ 26, 28. The parties also dispute the quality of Plaintiff’s performance from May through October 2018. Compare Def. SUMF ¶¶ 21-26 with Pl. SUMF ¶¶ 17-19. On October 30, 2018, Plaintiff met with Davis and human resources representative Katie

Garippa (Garippa) to discuss her performance, and, at the end of this meeting, Plaintiff told them that she was pregnant. Compare Pl. SUMF ¶¶ 23-24 with Def. SUMF ¶¶ 89, 92. After this meeting, Davis, Campbell, and Garippa discussed how to address Plaintiff’s performance, and Campbell proposed “delivering [Plaintiff] an option for leaving AngioDynamics.” Def. SUMF ¶¶ 94-99; Dkt. No. 40-22 at 2-3. On November 5, 2018, Garippa wrote, “Overall, I strongly advise against separation.” Dkt. No. 40-22 at 2. Davis continued to coach Plaintiff and did not put her on a performance improvement plan (PIP). Def. SUMF ¶ 100. Plaintiff and Defendant disagree about Plaintiff’s performance during November 2018. Id. ¶¶ 100-09; Pl. Resp. SUMF ¶¶ 100-09. On December 6, 2018, Plaintiff began a PIP. Def. SUMF ¶ 111. On December 9, 2018, Plaintiff emailed Garippa regarding a separation package and attached a document with an EEOC

Case Number. Pl. Resp. SUMF ¶ 114; Dkt No. 40-48; Def. SUMF ¶ 115. The parties did not agree on a separation package. Pl. Resp. SUMF ¶ 117. On approximately December 13, 2018, Defendants began an investigation regarding Plaintiff’s allegations of discrimination in the document with the EEOC Case Number. Def. SUMF ¶¶ 118-21. The investigation concluded that none of Plaintiff’s allegations of discrimination, harassment, and retaliation were substantiated. Id. ¶ 121. Plaintiff completed the PIP successfully on January 28, 2019. Def. SUMF ¶¶ 111, 126-27. The parties disagree about whether Plaintiff had performance issues after she completed the PIP. Compare Def. SUMF ¶¶ 129-34 with Pl. Resp. SUMF ¶¶ 129-34. On February 1, 2019, Plaintiff filed a discrimination charge with the New York State Department of Human Rights, and on February 14, 2019, she notified AngioDynamics about the charge. Pl. SUMF ¶ 50. On the same day, Plaintiff presented a plan for several new products. Id. ¶ 51. The next day, AngioDynamics terminated Plaintiff’s employment. Id. ¶ 52. After Plaintiff

left the company, AngioDynamics hired Eric Del Vescovo as an APM. Dkt. No. 40-44 at 2.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United Mine Workers of America v. Gibbs
383 U.S. 715 (Supreme Court, 1966)
Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
Carnegie-Mellon University v. Cohill
484 U.S. 343 (Supreme Court, 1988)
Wilson v. Northwestern Mutual Insurance
625 F.3d 54 (Second Circuit, 2010)
Brod v. Omya, Inc.
653 F.3d 156 (Second Circuit, 2011)
Kevin Naylor v. Case and McGrath Inc.
585 F.2d 557 (Second Circuit, 1978)
Selevan v. New York Thruway Authority (NYTA)
711 F.3d 253 (Second Circuit, 2013)
Wright v. Goord
554 F.3d 255 (Second Circuit, 2009)
Hicks v. Baines
593 F.3d 159 (Second Circuit, 2010)
Rose v. Goldman, Sachs & Co., Inc.
163 F. Supp. 2d 238 (S.D. New York, 2001)
Chiaramonte v. Animal Medical Center
677 F. App'x 689 (Second Circuit, 2017)
Moorehead v. United States
88 Fed. Cl. 614 (Federal Claims, 2009)

Cite This Page — Counsel Stack

Bluebook (online)
Lauren LeBlanc v. AngioDynamics, Inc., Chad Campbell, Stephanie Pitts, and Chris Davis, Counsel Stack Legal Research, https://law.counselstack.com/opinion/lauren-leblanc-v-angiodynamics-inc-chad-campbell-stephanie-pitts-and-nynd-2026.